Maiwei Biotechnology (688062.SH): Injection 7MW4911 clinical trial application for FDA approval obtained.

Zhitong Finance News App, Maiwei Biotech (688062.SH) announced that the company has received the "Notice of Continuation of Clinical Studies" issued by the Food and Drug Administration (FDA) of the United States. The application for clinical trials of injectable 7MW4911 has officially obtained FDA approval and will be conducted according to the planned clinical research plan, namely the "Phase I/II study of the safety, pharmacokinetics, and efficacy of 7MW4911 in patients with advanced colorectal cancer and other advanced gastrointestinal tumors".